Literature DB >> 11444454

Use of inhaled nitric oxide for emergency Cesarean section in a woman with unexpected primary pulmonary hypertension.

C Decoene1, K Bourzoufi, D Moreau, F Narducci, F Crepin, R Krivosic-Horber.   

Abstract

PURPOSE: Use of inhaled nitric oxide (iNO) could be of importance in emergency cases of primary pulmonary hypertension (PPH) in pregnant patients during labour and delivery. iNO acts as a selective pulmonary bed vasodilator avoiding systemic hemodynamic effects due to its ease of administration. Pulmonary bed vasodilation improves right ventricular function directly and left ventricular function indirectly. CLINICAL FEATURES: We report the case of a pregnant patient with unexpected PPH in whom an emergency Cesarean section (CS) had to be performed. PPH was diagnosed on admission as she arrived in active labour at 34 weeks gestational age. An emergency CS was performed under epidural anesthesia for breech presentation . All along labour, delivery and the first 24 hr, iNO was administered via a noninvasive ventilation device. CS was uneventful. A severe pulmonary hypertensive crisis was observed 12 hr after delivery and resolved with an increase of iNO concentration and administration of isoprenalin. The patient and baby returned home on day ten.
CONCLUSION: The ease of administration of iNO allowed the optimal control of pulmonary arterial hypertension. No interaction with epidural anesthesia was observed. Use of iNO can improve the management of urgent CS in women with unexpected PPH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444454     DOI: 10.1007/BF03016836

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  8 in total

Review 1.  Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report.

Authors:  Darren B Taichman; Joe Ornelas; Lorinda Chung; James R Klinger; Sandra Lewis; Jess Mandel; Harold I Palevsky; Stuart Rich; Namita Sood; Erika B Rosenzweig; Terence K Trow; Rex Yung; C Gregory Elliott; David B Badesch
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

Review 2.  CO and NO pulmonary diffusing capacity during pregnancy: Safety and diagnostic potential.

Authors:  Gerald S Zavorsky; Arlin B Blood; Gordon G Power; Lawrence D Longo; Raul Artal; Emanuel J Vlastos
Journal:  Respir Physiol Neurobiol       Date:  2010-02-10       Impact factor: 1.931

3.  [Management of cardiac high risk pregnancy. Caesarean section in a primagravida with cyanotic cardiac defect].

Authors:  S Kramer; T Schröder; M Schuster; V Stangl; I Correns; W Sanad; T Volk
Journal:  Anaesthesist       Date:  2011-01       Impact factor: 1.041

Review 4.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

Review 5.  Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure.

Authors:  Angel Coz Yataco; Melina Aguinaga Meza; Ketan P Buch; Margaret A Disselkamp
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 6.  Pregnancy Considerations in the Multidisciplinary Care of Patients with Pulmonary Arterial Hypertension.

Authors:  Julie Coursen; Catherine E Simpson; Monica Mukherjee; Arthur J Vaught; Shelby Kutty; Tala K Al-Talib; Malissa J Wood; Nandita S Scott; Stephen C Mathai; Garima Sharma
Journal:  J Cardiovasc Dev Dis       Date:  2022-08-11

7.  Anaesthesia for caesarean section in the presence of multivalvular heart disease and severe pulmonary hypertension: a case report.

Authors:  Demet Coskun; Ahmet Mahli; Sibel Korkmaz; Figen S Demir; Gozde Karaca Inan; Dilek Erer; M Emin Ozdogan
Journal:  Cases J       Date:  2009-12-22

8.  Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute.

Authors:  Anna R Hemnes; David G Kiely; Barbara A Cockrill; Zeenat Safdar; Victoria J Wilson; Manal Al Hazmi; Ioana R Preston; Mandy R MacLean; Tim Lahm
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.